Predictors of the Short-Term Effect of Isoleucine–Proline–Proline/Valine–Proline–Proline Lactotripeptides from Casein on Office and Ambulatory Blood Pressure in Subjects with Pharmacologically Untreated High-Normal Blood Pressure or First-Degree Hypertension

REFERENCES

• Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112:3547–3553.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, . Global burden of hypertension: analysis of worldwide datra. Lancet 2005; 365:217–223.
   PubMed Web of Science ®Google Scholar
• Lawes CM, Vanders HS, Rodgers A. Global burden of blood-pressure related disease, 2001. Lancet 2008; 371:1513–1518.
   PubMed Web of Science ®Google Scholar
• McInnes GT. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl 2005; 23:S3–S8.
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A, . ESH-ESC task force on the management of arterial hypertension: ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007; 25(9):1751–1762.
   PubMed Web of Science ®Google Scholar
• Appel LJ, Giles TD, Black HR, . American society of hypertension writing group: ASH position paper: dietary approaches to lower blood pressure. J Clin Hypertens 2009; 11(7):358–368.
   PubMedGoogle Scholar
• Cicero AFG, Gaddi AV, Borghi C. Complementary Medicine for hypertension: what evidence for herbalist suggestions? Evaluation of risks and potential applications. Evid Based Integr Med 2005; 2:47–55.
   Google Scholar
• Cicero AFG, Ertek S. Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? Med J Nutr Metab 2008; 1(2):85–93.
   Google Scholar
• Cicero AFG, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids their potential role in blood pressure prevention and management. Curr Vasc Pharmacol 2009; 7:330–337.
   PubMed Web of Science ®Google Scholar
• Boelsma E, Kloek J. Lactotripeptides and antihypertensive effects: a critical review. Br J Nutr 2009; 101(6):776–786.
   PubMed Web of Science ®Google Scholar
• Van Mierlo LA, Koning MM, van der Zander K, Draijer R. Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies. Am J Clin Nutr 2009; 89(2):617–623.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Rosticci M, Veronesi M, . Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, crossover clinical trial. J Med Food. 2010; 13(6):1363–1368.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Rosticci M, Gerocarni B, . Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertens Res 2011; 34(9):1035–1040.
   PubMed Web of Science ®Google Scholar
• Pickering TG, Hall JE, Appel LJ, . Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111(5):697–716.
   PubMed Web of Science ®Google Scholar
• Madin K, Iqbal P. Twenty four hour ambulatory blood pressure monitoring: a new tool for determining cardiovascular prognosis. Postgrad Med J 2006; 82(971):548–551.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens. 2011; 25(7):425–436.
   PubMed Web of Science ®Google Scholar
• Van der Zander K, Bots ML, Bak AA, Koning MM, de Leeuw PW. Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. Am J Clin Nutr 2008; 88(6):1697–1702.
   PubMed Web of Science ®Google Scholar
• Usinger L, Jensen LT, Flambard B, Linneberg A, Ibsen H. The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension. J Hum Hypertens. 2010; 24(10):678–683.
   PubMed Web of Science ®Google Scholar
• Wuerzner G, Peyrard S, Blanchard A, Lalanne F, Azizi M. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. J Hypertens 2009; 27(7):1404–1409.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Mizutani J, Sasaki K, Yamamoto N, Takazawa K. Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic index: a preliminary study. J Med Food 2009; 12(6):1–6.
   PubMedGoogle Scholar
• Ehlers PI, Nurmi L, Turpeinen AM, Korpela R, Vapaatalo H. Casein-derived tripeptide Ile-Pro-Pro improves angiotensin-(1-7)- and bradykinin-induced rat mesenteric artery relaxation. Life Sci 2011; 88(5–6):206–211.
   PubMed Web of Science ®Google Scholar
• Hirota T, Ohki K, Kawagishi R, . Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res. 2007; 30(6):489–496.
   PubMed Web of Science ®Google Scholar